Karyopharm Therapeutics Inc (KPTI) Downgraded by ValuEngine
Karyopharm Therapeutics Inc (NASDAQ:KPTI) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.
A number of other research analysts have also issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 price objective on shares of Karyopharm Therapeutics in a report on Monday, May 15th. Jefferies Group LLC reiterated a “buy” rating and issued a $17.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, April 7th. Robert W. Baird reiterated an “outperform” rating and issued a $15.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday, April 6th. Wedbush reiterated an “outperform” rating and issued a $14.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, April 5th. Finally, Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Karyopharm Therapeutics currently has a consensus rating of “Buy” and an average price target of $14.32.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 4.56% on Thursday, reaching $9.01. 146,297 shares of the company were exchanged. The company’s 50-day moving average price is $10.27 and its 200 day moving average price is $10.24. The company’s market cap is $424.53 million. Karyopharm Therapeutics has a 12 month low of $6.27 and a 12 month high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.04. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.02 million. During the same period in the previous year, the business posted ($0.75) EPS. On average, equities research analysts expect that Karyopharm Therapeutics will post ($2.68) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Karyopharm Therapeutics Inc (KPTI) Downgraded by ValuEngine” was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/05/25/karyopharm-therapeutics-inc-kpti-downgraded-by-valuengine.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KPTI. Teachers Advisors LLC raised its position in Karyopharm Therapeutics by 915.0% in the first quarter. Teachers Advisors LLC now owns 420,563 shares of the company’s stock valued at $5,400,000 after buying an additional 379,127 shares during the last quarter. Iguana Healthcare Management LLC purchased a new position in Karyopharm Therapeutics during the first quarter valued at about $3,531,000. EAM Investors LLC purchased a new position in Karyopharm Therapeutics during the first quarter valued at about $3,462,000. Baker BROS. Advisors LP purchased a new position in Karyopharm Therapeutics during the third quarter valued at about $2,111,000. Finally, Palo Alto Investors LLC raised its position in Karyopharm Therapeutics by 6.4% in the first quarter. Palo Alto Investors LLC now owns 3,406,475 shares of the company’s stock valued at $43,739,000 after buying an additional 206,079 shares during the last quarter. Hedge funds and other institutional investors own 56.97% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.